C. novyi for the treatment of solid tumors in non-human animals

Patent metadata

Field	Value
Publication number	US-12433920-B2
Application number	US-201414781270-A
Country	US
Kind code	B2
Filing date	Mar 28, 2014
Priority date	Mar 29, 2013
Publication date	Oct 7, 2025
Grant date	Oct 7, 2025

Abstract

The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi , preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi , preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.

First claim

What is claimed is:

1. A method for debulking a solid tumor present in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi colony forming units (CFUs) comprising 1×10 6 -1×10 10 CFUs suspended in a pharmaceutically acceptable carrier or solution, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

2. The method according to claim 1 , wherein the unit dose comprises from 1×10 7 -1×10 8 C. novyi CFUs.

3. The method according to claim 1 , wherein the unit dose comprises 1×10 8 C. novyi CFUs.

4. The method according to claim 1 , wherein the C. novyi CFUs are selected from the group consisting of vegetative and spore forms.

5. The method according to claim 1 , wherein the C. novyi is C. novyi NT.

6. The method according to claim 5 , wherein the unit dose comprises 1×10 6 -1×10 10 C. novyi NT spores.

7. The method according to claim 5 , wherein the unit dose comprises from 1×10 7 -1×10 8 C. novyi NT spores.

8. The method according to claim 5 , wherein the unit dose comprises 1×10 8 C. novyi NT spores.

9. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at a single location into the tumor.

10. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at multiple unique locations into the tumor.

11. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at 1-5 unique locations into the tumor.

12. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at 5 or more unique locations into the tumor.

13. The method according to claim 1 , wherein 2-10 treatment cycles are administered.

14. The method according to claim 1 , wherein 2-4 treatment cycles are administered.

15. The method according to claim 1 , wherein an interval between each treatment cycle is about 5-100 days.

16. The method according to claim 1 , wherein an interval between each treatment cycle is about 7 days.

17. The method according to claim 6 further comprising administering IV fluids to the non-human animal before, during, and/or after each administration of the C. novyi NT spores.

18. The method according to claim 6 , wherein 2-4 treatment cycles are administered.

19. The method according to claim 1 further comprising administering IV fluids to the non-human animal before, during, and/or after each administration of the C. novyi CFUs.

20. The method according to claim 1 further comprising providing the non-human animal with a first course of antibiotics for a period of time and at a dosage that is effective to treat or alleviate an adverse side effect selected from the group consisting of infections, vomiting, hematochezia, fever, and combinations thereof caused by the C. novyi CFUs.

21. The method according to claim 20 , wherein the antibiotics are administered for two weeks post C. novyi administration.

22. The method according to claim 20 , wherein the antibiotics are selected from the group consisting of amoxicillin, clavulanate, metronidazole, and combinations thereof.

23. The method according to claim 20 further comprising providing the non-human animal with a second course of antibiotics for a period of time and at a dosage that is effective to treat or alleviate an adverse side effect selected from the group consisting of infections, vomiting, hematochezia, fever, and combinations thereof caused by the C. novyi.

24. The method according to claim 23 , wherein the second course of antibiotics is initiated after completion of the first course of antibiotics and is carried out for 1-6 months.

25. The method according to claim 23 , wherein the second course of antibiotics is initiated after completion of the first course of antibiotics and is carried out for 3 months.

26. The method according to claim 23 , wherein the antibiotic used in the second course is doxycycline.

27. The method according to claim 1 , wherein the solid tumor is resistant to a therapy selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, and combinations thereof.

28. The method according to claim 1 , wherein the solid tumor is refractory to standard therapy or the solid tumor is without an available standard therapy.

29. The method according to claim 1 , wherein the unit dose of C. novyi induces a potent localized inflammatory response and an adaptive immune response in the non-human animal.

30. The method according to claim 1 , wherein the non-human animal is selected from the group consisting of domesticated animals and farm animals.

31. The method according to claim 30 , wherein the domesticated animals are selected from the group consisting of dogs, cats, and horses.

32. The method according to claim 30 , wherein the domesticated animal is a dog.

33. The method according to claim 30 , wherein the farm animals are selected from the group consisting of sheep, pigs, and cattle.

34. A method for debulking a solid tumor that has metastasized to one or more sites in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi NT colony forming units (CFUs) comprising 1×10 6 -1×10 10 CFUs suspended in a pharmaceutically acceptable carrier or solution, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

35. The method according to claim 34 , wherein at least one site is distal to the original solid tumor.

36. A method for debulking a solid tumor present in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi NT spores comprising 1×10 8 spores per cycle, each unit dose of C. novyi NT being suspended in a pharmaceutically acceptable carrier or solution, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

37. A method for treating or ameliorating an effect of a mast cell tumor present in a dog comprising administering a plurality of treatment cycles of a unit dose of C. novyi NT spores, each treatment cycle comprising injecting one unit dose of 1×10 8 C. novyi NT spores into the mast cell tumor, each unit dose of C. novyi NT being suspended in a pharmaceutically acceptable carrier or solution, and wherein the C. novyi NT is the only administered anti-tumor treatment.

38. A method for ablating a solid tumor present in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi CFUs comprising 1×10 6 -1×10 10 CFUs suspended in a pharmaceutically acceptable carrier or solution, wherein the tumor is ablated leaving a margin of normal tissue, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

39. The method according to claim 38 , wherein the non-human animal

Assignees

• Biomed Valley Discoveries Inc
• Univ Johns Hopkins

Inventors

• Saha Saurabh
• Zhou Shibin
• Vogelstein Bert
• Kinzler Kenneth W

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/65

  Tetracyclines · CPC title

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title